D3 Bio Raises $62 Million in Series A+ Round for Next-Gen KRAS G12C Inhibitor
Summary
D3 Bio, a Shanghai oncology biotech, closed a $62 million Series A+ financing round, a large amount for an early-stage company in the past few years. The funding will use the funds to ramp up development of D3 Bios preclinical assets and a global clinical trial of D3S-001, a next-gen small molecule KRAS G12C inhibitor that the company believes has best-in-class potential. The A+ round was led by Medicxi, a European life sciences investment firm. In 2020, D3 Bio raised an impressive $200 million in a Series A round. More details.... Share this with colleagues:This article is available for purchase -Sorry this page is available to subscribers only.If youre not a subscriber why not subscribe today?If you are already a subscriber, please login.If you believe you should have received this message in error, please contact us.